PEPperPrint Logo
The company PEPperPRINT, headquartered in Heidelberg/Germany, has developed a technology to produce 3D molecular printing of peptide libraries by coupling individual amino acids in situ to form linear peptide chains.

The advantage of this technology is the sheer unlimited diversity of peptide sequences that can be synthesized in parallel, using only very small material quantities at minimal cost.

In contrast to the regular peptide array production, which requires additional synthesis and spotting steps PEPperPRINT prints the desired amino acid pattern directly, level by level, on a chip. Between the printing steps, toner particles are melted to release the activated amino acids. The peptide bond can be formed either by the linker or the previous amino acid that was printed on the same position. After washing and de-protection of the peptide N-terminus, the next amino acid pattern is printed and coupled. By repeating this cycle, up to 30.000 different peptides in duplicate consisting of up to 20 amino acids are synthesized in parallel. The huge sequence variety accompanied with low synthesis costs is unique and allows the generation of large peptide libraries for e.g. serum biomarker screens or peptide-target binder discovery. In addition, due to the digital printing flexibility, custom PEPperCHIP® Peptide Microarrays can be manufactured and supplied in any quantity, from single microarrays to hundreds of chips within only 3-5 weeks. Furthermore, the peptide content can be easily adapted or adjusted from one to the next project.

PEPperCHIP laser printing platform


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA